A gene that contributes to cancer and cardiovascular development may be the cause of swelling in the most common type of aortic aneurysm, and could be the key to treatment.
On 3 October, the UK’ National Institute for Health and Clinical Excellence (NICE) opened a consultation on a new draft quality standard for the management of venous thromboembolic (VTE) diseases. The draft quality standard describes markers of high-quality, cost-effective care that, when delivered collectively, should contribute to improving the effectiveness, safety and experience of care for people with venous thromboembolic diseases.
Early results from ACST-2 suggest that modern carotid artery stenting and carotid endarterectomy have a low serious morbidity and mortality, according to early results of the Asymptomatic Carotid Surgery Trial 2 (ACST-2).
The US Food and Drug Administration (FDA) has given approval to Bolton Medical for its Relay Thoracic Stent-Graft with Plus Delivery System which is designed to be used in the treatment of thoracic aortic aneurysms and penetrating atherosclerotic ulcers.
Boston Scientific has launched in European countries the Promus Element Plus BTK (below the knee) Everolimus-Eluting Stent System for the treatment of certain severe peripheral artery lesions. The drug-eluting stent has CE mark approval for both monorail and over-the-wire versions and will be available immediately.
The US Food and Drug Administration (FDA) has given 510(k) clearance to Aptus Endosystems for its thoracic-length HeliFX Aortic Securement System used in the fixation and sealing of thoracic endovascular aneurysm repair (TEVAR) endografts.
Bayer HealthCare is introducing its Jetstream Atherectomy System for the treatment of peripheral arterial disease in the lower limbs at CIRSE (15–19 September, Lisbon, Portugal).
Covidien announced at CIRSE 2012 (15–19 September, Lisbon, Portugal) the launch of the Viance Crossing Catheter and Enteer Re-entry System for treating chronic total occlusions (CTOs). The devices are now available in the United States, the European Union and other select international markets.
Zaragoza, septiembre de 2012.- Con la ponencia titulada “Endoablación mediante el uso de vapor”, el Dr. Gerardo Pastor Mena, cirujano vascular de la Clínica Quirón de Zaragoza, ha presentado en el XVI Congreso Internacional FVL de Chile su experiencia con la técnica de vapor de agua (SVS).
On 11 September 2012, Healthpoint Biotherapeutics announced the initiation of a phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared to those receiving vehicle control plus compression therapy over the 12-week treatment period.
Bio DG announced on 10 September 2012 that its patent for a novel metal system for use as biodegradable material in developing implantable medical devices was granted by the US Patent Office on 21 August 2012.
Biotronik has introduced its Pulsar stent technology in a 0.035”/6F platform and Passeo-14 balloon catheter, a dedicated 0.014” infrapopliteal percutaneous transluminal angioplasty (PTA) catheter, for lower limb treatment.
Following the success of BIOTRONIK s Pulsar-18 0.018"/4F-platform self-expanding stent system, the company has now introduced its Pulsar stent technology in a 0.035"/6F platform. With this, BIOTRONIK is offering even more physicians its high qualitative stent technology with its high technical success and encouraging clinical performance.
Endologix has announced CE mark approval of the current version of the Nellix EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms.
The Vascular Society of Great Britain & Ireland (VSGBI) and the Royal College of Physicians have released the UK Carotid Endarterectomy Audit Round 4. This fourth public report from the Carotid Interventions Audit demonstrates continuing improvement in the service that hospital teams provide to patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos